

*A1* RECEPTOR" to THERAPEUTIC APPLICATIONS FOR CCR5 CHEMOKINE  
RECEPTORS

At page 1, please delete at the top of the page "VANMA51.001".

At page 1, please delete the text from "BACKGROUND" to "filed March 3, 1997" and  
insert therefore the following paragraph:

--RELATED APPLICATIONS

*A2* This application claims priority under 35 U.S.C. § 120 to U.S. Patent Application Serial  
No. 09/626,939, filed July 27, 2000, which claims priority under 35 U.S.C. § 120 to U.S. Patent  
Application Serial No. 08/833,752, filed April 9, 1997, which claims priority under 35 U.S.C.  
§ 119(a)-(d) to EP 96870021.1, filed March 1, 1996, and EP 96870102.9, filed August 6, 1996.--

A marked-up version of page 1 of the specification is attached herewith showing where  
changes have been made.

In the Claims

*Rule 126* Please **cancel** claims <sup>27</sup>1-~~38~~.

Please **add** claims <sup>1-13</sup>~~39-51~~. 28-40

*A3* ~~28-39~~ 1. A method for decreasing the infectivity of a cell expressing a CCR5 chemokine receptor  
by an HIV virus, said method comprising delivering to said cell a CCR5 chemokine  
receptor modulator.

~~29-40~~ 2. The method according to claim 39, wherein said CCR chemokine receptor modulator  
comprises an antagonist of said CCR5 chemokine.

~~30-41~~ 3. The method according to claim 39, wherein said modulator is a polypeptide.